- Home
- NPV vs NBTX Comparison
NPV vs NBTX Comparison
Compare NPV & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPV
- NBTX
- Stock Information
- Founded
- NPV 1993
- NBTX 2003
- Country
- NPV United States
- NBTX France
- Employees
- NPV N/A
- NBTX N/A
- Industry
- NPV Investment Managers
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- NPV Finance
- NBTX Health Care
- Exchange
- NPV Nasdaq
- NBTX Nasdaq
- Market Cap
- NPV 241.2M
- NBTX 201.9M
- IPO Year
- NPV N/A
- NBTX 2020
- Fundamental
- Price
- NPV $13.17
- NBTX $3.47
- Analyst Decision
- NPV
- NBTX Strong Buy
- Analyst Count
- NPV 0
- NBTX 2
- Target Price
- NPV N/A
- NBTX $11.50
- AVG Volume (30 Days)
- NPV 38.9K
- NBTX 51.6K
- Earning Date
- NPV 01-01-0001
- NBTX 12-24-2024
- Dividend Yield
- NPV 3.90%
- NBTX N/A
- EPS Growth
- NPV N/A
- NBTX N/A
- EPS
- NPV N/A
- NBTX N/A
- Revenue
- NPV N/A
- NBTX $45,220,186.00
- Revenue This Year
- NPV N/A
- NBTX N/A
- Revenue Next Year
- NPV N/A
- NBTX N/A
- P/E Ratio
- NPV N/A
- NBTX N/A
- Revenue Growth
- NPV N/A
- NBTX 526.17
- 52 Week Low
- NPV $8.92
- NBTX $2.76
- 52 Week High
- NPV $11.55
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- NPV 41.83
- NBTX 53.02
- Support Level
- NPV $13.30
- NBTX $3.28
- Resistance Level
- NPV $13.72
- NBTX $3.69
- Average True Range (ATR)
- NPV 0.15
- NBTX 0.24
- MACD
- NPV -0.05
- NBTX 0.10
- Stochastic Oscillator
- NPV 0.00
- NBTX 96.77
About NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.